Positive Response Activity Seen With Datopotamab Deruxtecan in Advanced TNBC
December 08, 2021

Positive response data were seen when patients with advanced or metastatic triple-negative breast cancer were treated with datopotamab deruxtecan.

Reflections on Future Treatment Strategies for HER2+ mBC
December 08, 2021

Experts close out their discussion on the management of HER2+ metastatic breast cancer by highlighting their hopes for future treatment strategies.

Patient Case #3: Sequencing Therapy and Monitoring Results
December 08, 2021

Centering their conversation on a patient case, experts discuss the sequencing and monitoring of therapy in patients with HER2+ metastatic breast cancer.

Audience Questions on Selecting Optimal Therapy for mBC
December 08, 2021

Panelists field questions from a live audience regarding the optimal selection of therapy for patients with metastatic breast cancer.

Greater PFS Benefit Noted in Chinese Patients Receiving Entinostat Combo Vs Placebo for HR+ Breast Cancer
December 08, 2021

Results of a phase 3 trial presented at 2021 SABCS indicated that entinostat plus exemestane improved progression-free survival for Chinese patients with advanced hormone receptor–positive breast cancer vs placebo.

Highlights From the 2021 European Hematology Association Congress on Multiple Myeloma
December 08, 2021

Nina Shah, MD, highlights some of the major takeaways in multiple myeloma from the 2021 European Hematology Association Congress.

Oncology Peer Review On-The-Go: Improving Testing Access and Guiding Treatment Options with TrialJectory
December 07, 2021

The latest podcast episode of Oncology Peer Review On-The-Go features a conversation with Tzvia Bader and Karine Perreault on TrialJectory’s platform, which seeks to guide patients with cancer on their treatment journey.

Adjuvant Palbociclib Plus Endocrine Therapy Did Not Show Benefit in Early HR+ HER2 Negative Breast Cancer
December 07, 2021

Patients with hormone receptor-positive, HER2-negative early breast cancer did not see a benefit when adjuvant palbociclib was added to standard endocrine therapy.

Treatment with Pembrolizumab/Chemo Combo May Be a Standard of Care in mTNBC
December 07, 2021

Patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer derived a statistically significant survival benefit following treatment with pembrolizumab and chemotherapy.

Metformin Does Not Improve Outcomes in Early Hormone Receptor–Positive or –Negative Breast Cancer
December 07, 2021

A phase 3 trial analysis found that metformin does not improve invasive disease-free survival or overall survival rates for patients, regardless of hormone receptor status.